<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977089</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-07-01</org_study_id>
    <nct_id>NCT04977089</nct_id>
  </id_info>
  <brief_title>Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital</brief_title>
  <official_title>Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic coronary syndrome (CCS) is a newly described classification devised by the European&#xD;
      Society of Cardiology (ESC) 2019 to replace the term &quot;Stable Coronary Artery Disease (CAD).&#xD;
&#xD;
      The main reason for effecting the change is the term is thought to better describe the&#xD;
      disease process and encompass a wider spectrum of clinical, pharmacological, and&#xD;
      pathophysiological entities.&#xD;
&#xD;
      Using this new term, the disease atherosclerosis manifests as CAD is categorized into Acute&#xD;
      Coronary Syndrome (ACS) and CCS.&#xD;
&#xD;
      The main focus of introducing the concept of CCS is on the fact that CAD is a continuous&#xD;
      phenomenon involving intravascular plaque aggregation and progression which has different&#xD;
      evolutionary phases.&#xD;
&#xD;
      Dyslipidemia is recognized as a prominent risk factor for cardiovascular (CV) disease.&#xD;
&#xD;
      It is characterized by an elevation of serum total cholesterol (TC), low-density lipoprotein&#xD;
      cholesterol (LDL-C), or triglycerides (TG) and reduced serum high-density lipoprotein&#xD;
      cholesterol (HDL-C) concentration .&#xD;
&#xD;
      Genetically determined and metabolically induced disturbances in lipid metabolism, as&#xD;
      manifested in several types of dyslipidemia, have been shown to be causally related to the&#xD;
      development of coronary artery disease (CAD).&#xD;
&#xD;
      A diversity of clinical and angiographic studies has been made to evaluate the linkage&#xD;
      between plasma lipid-control therapy in the development of recurrent cardiovascular events.&#xD;
&#xD;
      Independent predictors of recurrent CVD events or death include age, smoking, hypertension&#xD;
      (HTN), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of&#xD;
      medications recommended by current treatment guidelines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dyslipidemia in chronic coronary syndrome</measure>
    <time_frame>one year</time_frame>
    <description>Pattern of dyslipidemia among patients with chronic coronary syndromes at sohag university hospital.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Ischemic heart disease patients .</arm_group_label>
    <description>Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>lipid profile test .</intervention_name>
    <description>Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )</description>
    <arm_group_label>Ischemic heart disease patients .</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        I examine cross sectional study which classify 100 patients with chronic coronary syndrome&#xD;
        into:&#xD;
&#xD;
        two main groups :&#xD;
&#xD;
          -  patient on statin therapy.&#xD;
&#xD;
          -  patient not on statin therapy. _And determine if patints in sohag university hospital&#xD;
             could achive the target lipid profile level of their group according to 2019 ESC/EAS&#xD;
             Guidelines for the management of dyslipidaemia.&#xD;
&#xD;
        I classify 100 patients with chronic coronary syndrome into:&#xD;
&#xD;
        two main groups :&#xD;
&#xD;
          -  patient on statin therapy.&#xD;
&#xD;
          -  patient not on statin therapy. _And determine if patints in sohag university hospital&#xD;
             could achive the target lipid profile level of their group according to 2019 ESC/EAS&#xD;
             Guidelines for the management of dyslipidaemia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients have chronic coronary disease at Sohag University hospital who recieve&#xD;
             drugs of anti hyperlipidemia .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with first attack of acute coronary syndrome .&#xD;
&#xD;
          -  Young patients &lt;18 years .&#xD;
&#xD;
          -  Old patients &gt;65 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Islam M Farrag, resident</last_name>
    <phone>01092029333</phone>
    <email>islam010011@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ali M Ahmed, professor</last_name>
    <phone>01003459738</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama R ElSherif, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Darroudi S, Saberi-Karimian M, Tayefi M, Arekhi S, Motamedzadeh Torghabeh A, Seyedzadeh Sani SMR, Moohebati M, Heidari-Bakavoli A, Ebrahimi M, Azarpajouh MR, Safarian M, A Ferns G, Esmaeili H, Parizadeh MR, Mokhber N, Mahdizadeh A, Mahmoudi AA, Sahebkar AH, Ghayour-Mobarhan M. Prevalence of combined and noncombined dyslipidemia in an Iranian population. J Clin Lab Anal. 2018 Oct;32(8):e22579. doi: 10.1002/jcla.22579. Epub 2018 Jun 21.</citation>
    <PMID>29926995</PMID>
  </reference>
  <reference>
    <citation>Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4242.</citation>
    <PMID>31504439</PMID>
  </reference>
  <reference>
    <citation>Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):221-230. doi: 10.1016/j.jcmg.2017.01.029. Epub 2017 Jul 25.</citation>
    <PMID>28624395</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Islam Mohamed Farrag</investigator_full_name>
    <investigator_title>resident doctor at internal medicine department sohag university hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

